Patient baseline data
| . | 60 mg (n = 26) . | 40 mg (n = 27) . | 30 mg (n = 28) . | 20 mg (n = 25) . | Total (n = 106) . | P . |
|---|---|---|---|---|---|---|
| Mean age at transplantation, y (SD) | 45.9 (8.9) | 48.1 (10.1) | 50.2 (6.6) | 51.4 (9.2) | 48.9 (8.9) | NS |
| Sex direction | NS | |||||
| Male to male | 6 | 6 | 5 | 6 | 23 | |
| Male to female | 3 | 5 | 6 | 8 | 22 | |
| Female to male | 10 | 9 | 10 | 5 | 34 | |
| Female to female | 7 | 7 | 7 | 6 | 27 | |
| Source | NS | |||||
| BM | 2 | 0 | 1 | 0 | 3 | |
| PB | 24 | 26 | 27 | 24 | 101 | |
| PB + BM | 0 | 1 | 0 | 1 | 2 | |
| CMV serostatus (D/R) | NS | |||||
| Pos/Pos | 14 | 11 | 15 | 11 | 51 | |
| Pos/Neg | 5 | 4 | 5 | 5 | 19 | |
| Neg/Pos | 1 | 6 | 2 | 5 | 14 | |
| Neg/Neg | 6 | 6 | 6 | 4 | 22 | |
| Disease | NS | |||||
| AML/ALL | 2 | 6 | 10 | 7 | 25 | |
| NHL | 8 | 9 | 10 | 7 | 34 | |
| HL | 5 | 5 | 2 | 2 | 14 | |
| CLL | 4 | 3 | 2 | 6 | 15 | |
| Plasma cell dyscrasia | 7 | 1 | 2 | 1 | 11 | |
| Other | 0 | 3 | 2 | 2 | 7 | |
| Status at transplantation | ||||||
| Advanced disease | 25 | 21 | 17 | 17 | 80 | .02 |
| Nonadvanced disease | 1 | 6 | 11 | 8 | 26 | |
| TNC infused, median (IQR) | 12.5 (9.8-17.8) | 8.2 (6.3-15.4) | 7.6 (6.0-10.0) | 11.1 (5.5-13.7) | 9.6 (6.3-12.9) | NS |
| CD34 infused, median (IQR) | 4.9 (3.5-6.0) | 4.6 (3.4-5.8) | 4.3 (3.4-5.1) | 5.4 (4.1-6.8) | 4.8 (3.5-6.0) | NS |
| . | 60 mg (n = 26) . | 40 mg (n = 27) . | 30 mg (n = 28) . | 20 mg (n = 25) . | Total (n = 106) . | P . |
|---|---|---|---|---|---|---|
| Mean age at transplantation, y (SD) | 45.9 (8.9) | 48.1 (10.1) | 50.2 (6.6) | 51.4 (9.2) | 48.9 (8.9) | NS |
| Sex direction | NS | |||||
| Male to male | 6 | 6 | 5 | 6 | 23 | |
| Male to female | 3 | 5 | 6 | 8 | 22 | |
| Female to male | 10 | 9 | 10 | 5 | 34 | |
| Female to female | 7 | 7 | 7 | 6 | 27 | |
| Source | NS | |||||
| BM | 2 | 0 | 1 | 0 | 3 | |
| PB | 24 | 26 | 27 | 24 | 101 | |
| PB + BM | 0 | 1 | 0 | 1 | 2 | |
| CMV serostatus (D/R) | NS | |||||
| Pos/Pos | 14 | 11 | 15 | 11 | 51 | |
| Pos/Neg | 5 | 4 | 5 | 5 | 19 | |
| Neg/Pos | 1 | 6 | 2 | 5 | 14 | |
| Neg/Neg | 6 | 6 | 6 | 4 | 22 | |
| Disease | NS | |||||
| AML/ALL | 2 | 6 | 10 | 7 | 25 | |
| NHL | 8 | 9 | 10 | 7 | 34 | |
| HL | 5 | 5 | 2 | 2 | 14 | |
| CLL | 4 | 3 | 2 | 6 | 15 | |
| Plasma cell dyscrasia | 7 | 1 | 2 | 1 | 11 | |
| Other | 0 | 3 | 2 | 2 | 7 | |
| Status at transplantation | ||||||
| Advanced disease | 25 | 21 | 17 | 17 | 80 | .02 |
| Nonadvanced disease | 1 | 6 | 11 | 8 | 26 | |
| TNC infused, median (IQR) | 12.5 (9.8-17.8) | 8.2 (6.3-15.4) | 7.6 (6.0-10.0) | 11.1 (5.5-13.7) | 9.6 (6.3-12.9) | NS |
| CD34 infused, median (IQR) | 4.9 (3.5-6.0) | 4.6 (3.4-5.8) | 4.3 (3.4-5.1) | 5.4 (4.1-6.8) | 4.8 (3.5-6.0) | NS |
SD indicates standard deviation; NS, not significant; BM, bone marrow; PB, peripheral blood; CMV, cytomegalovirus; D/R, donor/recipient; Pos, seropositive; Neg, seronegative; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; TNC, total nucleated cell count; and IQR, interquartile range.